[1] Semenza G L, Rue E A, Iyer N V, et al. Assignment of the hypoxia-inducible factor 1α gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q[J]. Genomics, 1996, 34(3):437-439.
[2] Wang G L, Semenza G L. Purification and characterization of hypoxia-inducible factor 1[J]. Journal of Biological Chemistry, 1995, 270(3):1230-1237.
[3] Benita Y, Kikuchi H, Smith A D, et al. An integrative genomics approach identifies hypoxia inducible factor-1(HIF-1)-target genes that form the core response to hypoxia[J]. Nucleic Acids Research, 2009, 37(14):4587-4602.
[4] Mole D R, Blancher C, Copley R R, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts[J]. Journal of Biological Chemistry, 2009, 284(25):16767-16775.
[5] Kim J W, Tchernyshyov I, Semenza G L, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase:A metabolic switch required for cellular adaptation to hypoxia[J]. Cell Metabolism, 2006, 3(3):177-185.
[6] Bai C, Sen P, Hofmann K, et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box[J]. Cell, 1996, 86(2):263-274.
[7] Hon W C, Wilson M I, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL[J]. Nature, 2002, 417(6892):975-978.
[8] Mcneill L A, Hewitson K S, Gleadle J M, et al. The use of dioxygen by HIF prolyl hydroxylase(PHD1)[J]. Bioorganic & Medicinal Chemistry Letters, 2002, 12(12):1547-1550.
[9] Mahon, P C. FIH-1:A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity[J]. Genes & Development, 2001, 15(20):2675-2686.
[10] Hewitson K S, Mcneill L A, Riordan M V, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family[J]. Journal of Biological Chemistry, 2002, 277(29):26351-26355.
[11] Lando D, Peet D J, Gorman J J, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor[J]. Genes Development, 2002, 16(12):1466-1471.
[12] Muchnik E, Kaplan J. HIF prolyl hydroxylase inhibitors for anemia[J]. Expert Opinion on Investigational Drugs, 2011, 20(5):645-656.
[13] Hsieh M M, Linde N S, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques[J]. Blood, 2007, 110(6):2140-2147.
[14] Del Vecchio L, Locatelli F. Roxadustat in the treatment of anaemia in chronic kidney disease[J]. Expert Opinion on Investigational Drugs, 2018, 27(1):125-133.
[15] Haase V H. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism[J]. Hemodialysis International, 2017(21):110-124.
[16] Shyu K G, Wang M T, Wang B W, et al. Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat[J]. Cardiovascular Research, 2002, 54(3):576-583.
[17] Bergeron M, Gidday J M, Yu A Y, et al. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain[J]. Annals of Neurology, 2000, 48(3):285-296.
[18] Cha S T, Chen P S, Johansson G, et al. MicroRNA-519c suppresses hypoxia-inducible factor-1α expression and tumor angiogenesis[J]. Cancer Research, 2010, 70(7):2675-2685.
[19] Gravdal K, Halvorsen O J, Haukaas S A, et al. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer[J]. Cancer Research, 2009, 69(11):4708-4715.
[20] Ryan H E, Poloni M, Mcnulty W, et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth[J]. Cancer Research, 2000, 60(15):4010-4015.
[21] Baba Y, Nosho K, Shima K, et al. HIF1A Overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers[J]. American Journal of Pathology, 2010, 176(5):2292-2301.
[22] Griffiths E A, Pritchard S A, Mcgrath S M, et al. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.[J]. British Journal of Cancer, 2007, 96(9):1377.
[23] Speisky D, Duces A, Bièche I, et al. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients[J]. Clinical Cancer Research, 2012, 18(10):2838-2849.
[24] Ajith T A. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer[J]. Journal of Basic and Clinical Physiology and Pharmacology, 2018, 30(1):11-18.
[25] Fan L, Diao L, Chen D. Expression of HIF-1 alpha and its relationship to apoptosis and proliferation in lung cancer[J]. Chinese Journal of Cancer, 2002, 21(3):254.
[26] Ghafar M A, Anastasiadis A G, Chen M W, et al. Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells[J]. The Prostate, 2003, 54(1):58-67.
[27] Talks K L, Turley H, Gatter K C, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages[J]. American Journal of Pathology, 2000, 157(2):411-421.
[28] Palayoor S T, Tofilon P J, Coleman C N. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells[J]. Clinical Cancer Research, 2003, 9(8):3150-3157.
[29] Mabjeesh N J, Escuin D, Lavallee T M, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF[J]. Cancer Cell, 2003, 3(4):363-375.
[30] Palazon A, Tyrakis P A, Macias D, et al. An HIF-1α/VEGF-A axis in cytotoxic T cells regulates tumor progression[J]. Cancer Cell. 2017, 32(5):669-683.
